Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Environ Microbiol. 2011 Apr;13(4):1010-7. doi: 10.1111/j.1462-2920.2010.02406.x. Epub 2011 Jan 18.

    Catabolic pathway for 2-nitroimidazole involves a novel nitrohydrolase that also confers drug resistance.

    Source

    School of Civil and Environmental Engineering, Georgia Institute of Technology, 311 Ferst Dr, Atlanta, GA 30332-0512, USA.

    Abstract

    Antibiotic resistance in pathogens can be mediated by catabolic enzymes thought to originate from soil bacteria, but the physiological functions and evolutionary origins of the enzymes in natural ecosystems are poorly understood. 2-Nitroimidazole (2NI) is a natural antibiotic and an analogue of the synthetic nitroimidazoles used for treatment of tuberculosis, Chagas' disease and cancer. Mycobacterium sp. JS330 was isolated from soil based on its ability to use 2NI as a sole growth substrate. The initial step in the degradation pathway is the hydrolytic denitration of 2NI to produce imidazol-2-one and nitrite. The amino acid sequence of 2NI nitrohydrolase is highly divergent from those of biochemically characterized enzymes, and it confers drug resistance when it is heterologously expressed in Escherichia coli. The unusual enzymatic reaction seems likely to determine the flux of nitroimidazole in natural ecosystems and also represents the discovery of a previously unreported drug resistance mechanism in soil before its identification in clinical situations.

    © 2011 Society for Applied Microbiology and Blackwell Publishing Ltd.

    PMID:
    21244596
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Blackwell Publishing

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk